About Our Lab
The Burridge lab works in the field of pharmacogenomics (precision medicine), cardio-oncology, cardiovascular disease, regenerative medicine, and cancer, primarily using human induced pluripotent stem cells (hiPSCs) as our model.
Our scientific interest is in developing next-generation tools to study the role of the genome in complex disease traits and the modulation of drug efficacy and toxicity. Using these tools we will be able to predict which patients will experience successful therapy or suffer adverse drug responses, validate the causal role of particular single nucleotide polymorphisms (SNPs), probe the mechanisms of action, and discover new drugs to overcome these complications. It is our ambition to translate these techniques to the clinic, to improve personalized patient care and drug efficacy, and to eliminate off-target toxicity.
Our major effort has been focused on SNPs involved in patient-specific chemotherapy-induced cardiovascular toxicity, particularly in breast cancer, pediatric cancer patients, and leukemia. We are interested in the genomic rationale for why some patients experience minimal side effects of their cancer treatments, whilst others encounter highly detrimental side effects. These side effects can include heart failure or arrhythmias, atherosclerosis, cognitive impairment, nerve damage, liver failure, or infertility. Our work has contributed to risk-based screening by functionally validating genetic changes that predispose a patient to specific drug responses.
In addition to this work, we are interested in cardiovascular diseases such as arrhythmia and regenerative medicine, repairing the heart after a heart attack or ameliorating the effects of heart failure. Our specific approach has been to apply developmental biology paradigms to induce direct reprogramming and proliferation.
Finally, we are interested in studying how heritable (germline) variation influences cancer progression, oncology drug efficacy, and acquisition of resistance.